LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Închisă

3.06 31.33

Rezumat

Modificarea prețului

24h

Curent

Minim

3.01

Maxim

3.11

Indicatori cheie

By Trading Economics

Venit

44M

-26M

Vânzări

-5.8M

42M

Marjă de profit

-61.388

Angajați

550

EBITDA

44M

-22M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+45.16% upside

Dividende

By Dow Jones

Următoarele câștiguri

25 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

8.3M

1.1B

Deschiderea anterioară

-28.27

Închiderea anterioară

3.06

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb. 2026, 22:36 UTC

Câștiguri

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb. 2026, 22:32 UTC

Câștiguri

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

23 feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb. 2026, 23:39 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb. 2026, 23:27 UTC

Câștiguri

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb. 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb. 2026, 22:31 UTC

Câștiguri

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb. 2026, 22:24 UTC

Câștiguri

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb. 2026, 22:20 UTC

Câștiguri

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparație

Modificare preț

Maravai LifeSciences Holdings Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

45.16% sus

Prognoză pe 12 luni

Medie 4.5 USD  45.16%

Maxim 4.5 USD

Minim 4.5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMaravai LifeSciences Holdings Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.02 / 2.115Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat